Where the name comes from
"Wolverine stack" is not a scientific or medical term. It is gym and biohacker slang for combining BPC-157 and TB-500, two peptides both studied for a role in tissue repair, and it borrows the name of a comic-book character known for healing from almost any injury. No study has tested this combination, and no regulator or manufacturer uses the name. It is worth saying plainly: the marketing name implies a healing power that no cited trial has demonstrated in a person.
This page explains what each peptide actually is and what the published evidence covers, without a dosing protocol.
BPC-157: what it is
BPC-157 (Body Protection Compound 157) is a synthetic 15 amino acid peptide, a pentadecapeptide, related to a fragment identified in human gastric juice. Its full sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It has been studied for more than two decades by one primary Croatian research group, whose animal work covers gut healing, protection of the stomach lining from NSAID damage, and repair of tendon, ligament, muscle and skin injuries.
The proposed mechanisms in that body of animal work include promoting new blood vessel growth (angiogenesis) at injury sites and interacting with pathways involved in tissue repair and the gut-brain axis. A 2025 literature and patent review and a 2021 review both summarise this work as extensive in rodents, with mechanism proposals well documented in that species, but without a confirmatory trial in humans.
TB-500: what it is
TB-500 is the research-chemical market name for a synthetic version of thymosin beta-4 (Tβ4), a small protein that occurs naturally throughout the body and is one of the most abundant actin-regulating proteins in cells. Actin is the protein scaffolding cells use to move and change shape, which is why thymosin beta-4 has been studied for a role in cell migration, new blood vessel formation, and wound healing, including work on skin, cornea and heart tissue in animal models.
Published reviews describe thymosin beta-4's biology across a wide range of preclinical work: dermal wound healing, platelet and endothelial cell function relevant to blood vessel repair, and effects reported in burns and wound research out of China as well as in Western journals. Thymosin beta-4 itself, as opposed to the research-chemical product marketed as TB-500, has had some early-phase human investigation from its original pharmaceutical developer, for conditions such as chronic wounds and dry eye, but this has not reached the scale or rigor of a completed Phase 3 programme, and it is not the same regulatory-grade product that research-chemical suppliers sell.
What the evidence supports for each, and what it does not
| BPC-157 Stocked locally | TB-500 Stocked locally | |
|---|---|---|
| What it is | 15 amino acid synthetic peptide, gastric-juice derived | Research-chemical name for synthetic thymosin beta-4 |
| Species studied | Almost entirely rats and mice | Cell culture and animal models; limited early human data on the parent molecule |
| Main research group | One Croatian laboratory, published over ~20 years | Multiple groups internationally on thymosin beta-4 biology |
| Human RCTs of the marketed research-chemical product | None published | None published |
| Approved medicine status | Not approved anywhere | Not approved anywhere |
Neither peptide has the kind of evidence base this site treats as strong: no human randomised controlled trial has been published for either one as sold in the research-chemical market, and animal results, however consistent within a lab, do not establish that an effect occurs the same way in people. The absence of reported problems in scattered small studies or anecdotal use is an absence of data, not evidence of safety, a distinction covered in the side effect management guide.
Why people reach for the pair specifically
The logic behind stacking the two, as it appears in gym and forum discussion, is that they were studied for overlapping but not identical things: BPC-157's animal literature leans toward gut lining, tendon and ligament repair, while thymosin beta-4's leans toward new blood vessel formation and cell migration across skin, cornea and cardiac tissue. The idea is that one might support structural repair while the other supports the blood supply around it. That is a mechanistic story built by connecting two separate sets of animal findings, not a conclusion either research group has drawn, and no study has tested whether combining the two produces anything beyond what each does alone.
The pair has not been tested as a pair
Every study cited for either peptide, in any species, gave that peptide alone. There is no published trial, animal or human, of BPC-157 and TB-500 administered together. Claims that the combination produces a stronger or faster effect than either compound alone are not supported by a cited study; they are an inference built on two separate evidence bases that were never tested jointly. That gap does not necessarily mean no interaction exists, only that nobody has published a trial that looked for one.
Side effects: an evidence gap, not a clean bill
Because neither peptide has completed a large controlled human trial, no reliable side-effect frequency exists for either one, and none exists for the combination. What is well established is the risk profile of the product itself rather than the molecule: research-grade vials are not manufactured or tested to pharmaceutical standards, and any injection carries a contamination risk that has nothing to do with what compound is inside the vial. The side effect management guide and sourcing principles cover this in more depth.
Status in the Philippines
Neither BPC-157 nor TB-500 is registered with FDA Philippines as a medicine, and neither is approved by the US FDA, the EMA, or any other major regulator. Both are not scheduled controlled substances under RA 9165, but that is a separate question from being approved for use. Both reach the Philippines exclusively through research-chemical suppliers, and both are sold as lyophilised powder intended for research use, not as a finished pharmaceutical product.
